Curated News
By: NewsRamp Editorial Staff
October 08, 2025

Oncotelic's Sapu-003 Marks First IV Deciparticle Everolimus Trial

Discuss on LinkedIn Discuss on Substack Discuss on Telegram participate in discussion on bluesky View History of this news story on GitHub
Original Source

TLDR

  • Oncotelic's Sapu-003 offers a competitive edge as the first intravenous Deciparticle everolimus formulation, potentially improving treatment efficacy for advanced breast cancer patients.
  • Sapu-003 utilizes a novel intravenous Deciparticle formulation of everolimus, an mTOR inhibitor, currently in Phase 1 trials for HR+/HER2– breast cancer patients in Australia.
  • This innovative cancer treatment approach could significantly improve outcomes for patients with advanced breast cancer and other mTOR-sensitive malignancies worldwide.
  • Oncotelic's groundbreaking intravenous Deciparticle technology represents the first clinical trial of its kind for everolimus delivery in cancer treatment.

Impact - Why it Matters

This development represents a potential breakthrough in cancer treatment delivery that could significantly improve patient outcomes. The intravenous Deciparticle formulation of everolimus addresses key limitations of current mTOR inhibitor therapies, potentially enhancing drug delivery efficiency and reducing side effects. For patients with advanced HR+/HER2– breast cancer and other mTOR-sensitive tumors, this innovation could mean more effective treatment options with better tolerability. The successful development of this technology could establish a new standard for targeted cancer therapy delivery, benefiting not only breast cancer patients but potentially those with various mTOR-dependent malignancies. As cancer remains a leading cause of mortality worldwide, advancements in drug delivery systems like this are crucial for improving survival rates and quality of life for cancer patients.

Summary

Oncotelic Therapeutics (OTCQB: OTLC), through its joint venture GMP Biotechnology Ltd. with Dragon Overseas Capital Ltd., has achieved a significant milestone with its subsidiary Sapu Nano presenting groundbreaking research at the 8th Australian Translational Breast Cancer Research Symposium. The company showcased its poster titled "Sapu-003: Novel Intravenous Deciparticle(TM) Everolimus Entering Phase 1 Study in Australia," marking the first clinical trial of an intravenous Deciparticle(TM) formulation of everolimus, an mTOR inhibitor used in breast cancer and other malignancies. This innovative approach represents a major advancement in cancer treatment delivery systems, with the trial (ACTRN12625001083482) now actively enrolling patients with advanced HR+/HER2– breast cancer or other mTOR-sensitive tumors at leading oncology centers across Australia.

The development of Sapu-003 is being conducted through strategic collaborations with SOCRU, Ingenū, and Medicilon, demonstrating the power of partnership in accelerating cancer research. Dr. Vuong Trieu, CEO of both Sapu Nano and Oncotelic, emphasized that this novel formulation represents a significant advance in the delivery of mTOR-targeted therapies. The company's mission focuses on addressing high-unmet-need cancers and rare pediatric indications with innovative therapeutic candidates. Oncotelic's robust portfolio benefits from Dr. Trieu's extensive intellectual property contributions, including more than 150 patent applications and 39 issued U.S. patents, positioning the company as a leader in oncology innovation through its joint venture structure and licensing strategies.

This announcement was distributed through BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio that provides comprehensive distribution services across multiple channels. The platform ensures maximum visibility for biotech and biomedical developments through wire solutions, article syndication to over 5,000 outlets, enhanced press release features, and social media distribution to millions of followers. This extensive reach helps bridge the gap between scientific innovation and public awareness, making critical medical advancements accessible to investors, healthcare professionals, and patients seeking new treatment options for challenging cancer conditions.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Oncotelic's Sapu-003 Marks First IV Deciparticle Everolimus Trial

blockchain registration record for this content.